| 1 | One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab | 1.8 | 37 | Citations (PDF) |
| 2 | Non‐scarring patchy alopecia: What else, apart from alopecia areata? | 1.1 | 1 | Citations (PDF) |
| 3 | Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in acute myeloid leukemia | 6.5 | 1 | Citations (PDF) |
| 4 | Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk | 24.1 | 41 | Citations (PDF) |
| 5 | Multilineage Dysplasia as Assessed by Immunophenotype in Acute Myeloid Leukemia: A Prognostic Tool in a Genetically Undefined Category | 3.8 | 4 | Citations (PDF) |
| 6 | Quick complete response achievement with venetoclax and azacitidine in a case of relapsed disseminated blastic plasmacytoid dendritic cell neoplasm | 1.5 | 9 | Citations (PDF) |
| 7 | Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial | 5.0 | 10 | Citations (PDF) |
| 8 | Chemotherapy-related nail toxicity | 1.5 | 0 | Citations (PDF) |
| 9 | Influence of Donor and Recipient Gender on Telomere Maintenance after Umbilical Cord Blood Cell Transplantation: A Study by the Gruppo Italiano Trapianto Di Midollo Osseo | 1.6 | 2 | Citations (PDF) |
| 10 | Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group | 1.6 | 32 | Citations (PDF) |
| 11 | Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)—a study of 1084 patients | 7.7 | 97 | Citations (PDF) |
| 12 | One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab TreatmentBlood, 2019, 134, 2231-2231 | 4.8 | 5 | Citations (PDF) |
| 13 | Occurrence of graft‐versus‐host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT | 7.3 | 30 | Citations (PDF) |
| 14 | “Best practice” for extracorporeal photopheresis in acute and chronic graft‐versus‐host disease by Societa’ Italiana di Emaferesi and Manipolazione Cellulare and Gruppo Italiano Trapianto Midollo Osseo: a national survey to ascertain its degree of application in Italian transplant centers | 0.8 | 10 | Citations (PDF) |
| 15 | Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT | 6.5 | 12 | Citations (PDF) |
| 16 | Evaluation of the prognostic role of tumour‐associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG‐PET assessment | 2.1 | 26 | Citations (PDF) |
| 17 | Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO) | 2.3 | 29 | Citations (PDF) |
| 18 | Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study | 3.6 | 8 | Citations (PDF) |
| 19 | Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen | 1.6 | 14 | Citations (PDF) |
| 20 | A life‐threatening ruxolitinib discontinuation syndrome | 6.5 | 42 | Citations (PDF) |
| 21 | A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity‐score weighted multicenter approach | 6.5 | 10 | Citations (PDF) |
| 22 | Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial | 62.1 | 566 | Citations (PDF) |
| 23 | Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System | 7.7 | 73 | Citations (PDF) |
| 24 | Inorganic Nanoparticles As Potential Regulators of Immune Response in Dendritic Cells | 3.0 | 41 | Citations (PDF) |
| 25 | The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study | 3.8 | 4 | Citations (PDF) |
| 26 | Long‐term follow‐up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation | 4.0 | 34 | Citations (PDF) |
| 27 | Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease | 2.1 | 48 | Citations (PDF) |
| 28 | Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MMBlood, 2016, 127, 2833-2840 | 4.8 | 221 | Citations (PDF) |
| 29 | Time related variations in stem cell harvesting of umbilical cord blood | 3.4 | 38 | Citations (PDF) |
| 30 | High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry | 1.6 | 9 | Citations (PDF) |
| 31 | New patterns of relapse in multiple myeloma: a case of “light chain escape” in which FLC predicted relapse earlier than urine and serum immunofixation | 2.3 | 12 | Citations (PDF) |
| 32 | Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission | 2.3 | 24 | Citations (PDF) |
| 33 | Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood—a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation | 24.1 | 35 | Citations (PDF) |
| 34 | Multilineage dysplasia as assessed by immunophenotype has no impact on clinical-biological features and outcome of NPM1-mutated acute myeloid leukemia | 0.4 | 5 | Citations (PDF) |
| 35 | Differences among young adults, adults and elderly chronic myeloid leukemia patients | 9.9 | 95 | Citations (PDF) |
| 36 | Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial | 2.3 | 21 | Citations (PDF) |
| 37 | FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk | 9.9 | 87 | Citations (PDF) |
| 38 | Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia | 7.7 | 214 | Citations (PDF) |
| 39 | The prognostic value of positron emission tomography performed after two courses (INTERIM‐PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL) | 6.5 | 50 | Citations (PDF) |
| 40 | Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ⩾10 years | 2.3 | 47 | Citations (PDF) |
| 41 | Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial | 27.4 | 170 | Citations (PDF) |
| 42 | Bortezomib based therapies and High Cut Off filter dyalysis (HCO) are effective in Multiple Myeloma patients with end stage renal failure | 1.0 | 0 | Citations (PDF) |
| 43 | Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide | 1.4 | 1 | Citations (PDF) |
| 44 | Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma | 0.8 | 59 | Citations (PDF) |
| 45 | Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma | 1.4 | 7 | Citations (PDF) |
| 46 | Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas | 1.4 | 8 | Citations (PDF) |
| 47 | CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia 2014, 86, 340-349 | | 12 | Citations (PDF) |
| 48 | Romiplostim before splenectomy in a patient with aggressive non‐Hodgkin lymphoma and poor response to platelet transfusions | 0.9 | 1 | Citations (PDF) |
| 49 | Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B‐cell lymphomas | 1.8 | 27 | Citations (PDF) |
| 50 | Kinetics of the use of cryopreserved autologous stem cell grafts: a GITMO-SIDEM survey | 2.3 | 8 | Citations (PDF) |
| 51 | Experts’ considerations on HLA‐haploidentical stem cell transplantation | 1.8 | 25 | Citations (PDF) |
| 52 | The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients | 7.7 | 292 | Citations (PDF) |
| 53 | Feasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen | 2.2 | 3 | Citations (PDF) |
| 54 | Skin CD30+ T cells and circulating levels of soluble CD30 are increased in patients with graft versus host disease | 5.0 | 4 | Citations (PDF) |
| 55 | Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value | 7.7 | 77 | Citations (PDF) |
| 56 | Primary Prophylaxis of Invasive Fungal Diseases in Allogeneic Stem Cell Transplantation: Revised Recommendations from a Consensus Process by Gruppo Italiano Trapianto Midollo Osseo (GITMO) | 1.6 | 59 | Citations (PDF) |
| 57 | Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) | 1.6 | 168 | Citations (PDF) |
| 58 | Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-RBlood, 2014, 123, 2333-2342 | 4.8 | 181 | Citations (PDF) |
| 59 | Open questions in the treatment of immune thrombocytopenic purpura | 0.0 | 0 | Citations (PDF) |
| 60 | Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome | 6.5 | 73 | Citations (PDF) |
| 61 | A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria | 1.6 | 7 | Citations (PDF) |
| 62 | Primary lymphoma of bone: outcome and role of surgery | 1.9 | 29 | Citations (PDF) |
| 63 | Long-term follow-up of concomitant treatment with romiplostim and warfarin in a patient with immune thrombocytopenia and severe cardiac comorbidities | 2.4 | 3 | Citations (PDF) |
| 64 | Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation | 1.4 | 4 | Citations (PDF) |
| 65 | The costs of mobilisation and collection of peripheral blood stem cells in multiple myeloma and lymphoma in an European country: Results from The Gruppo Italiano Trapianto Midollo Osseo (GITMO) and Società Italiana di Emaferesi e Manipolazione Cellulare (SIdEM) survey | 0.9 | 8 | Citations (PDF) |
| 66 | Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation | 9.9 | 96 | Citations (PDF) |
| 67 | Allogeneic Hematopoietic Cell Transplantation from Unrelated Donors in Multiple Myeloma: Study from the Italian Bone Marrow Donor Registry | 1.6 | 20 | Citations (PDF) |
| 68 | Treatment of experimental esophagogastric myotomy with bone marrow mesenchymal stem cells in a rat model | 2.6 | 8 | Citations (PDF) |
| 69 | The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo | 7.7 | 41 | Citations (PDF) |
| 70 | Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 studyBlood, 2013, 121, 5055-5063 | 4.8 | 184 | Citations (PDF) |
| 71 | Diagnosis of a T-lineage acute lymphoblastic leukemia through digitalized cell analysis of the pleural effusion | 0.3 | 1 | Citations (PDF) |
| 72 | Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine | 7.7 | 87 | Citations (PDF) |
| 73 | mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms | 2.3 | 85 | Citations (PDF) |
| 74 | Use of biosimilars in hematopoietic stem cells transplantation | 0.0 | 0 | Citations (PDF) |
| 75 | Does the reduced intensity conditioning regimen respect its promises? | 0.0 | 0 | Citations (PDF) |
| 76 | The Role of Bortezomib, Thalidomide and Lenalidomide in the Management of Multiple Myeloma | 3.6 | 14 | Citations (PDF) |
| 77 | Evidence for reduced angiogenesis in bone marrow in SSc: immunohistochemistry and multiparametric computerized imaging analysis | 1.9 | 16 | Citations (PDF) |
| 78 | Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients | 7.7 | 15 | Citations (PDF) |
| 79 | Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO studyBlood, 2012, 120, 1327-1333 | 4.8 | 111 | Citations (PDF) |
| 80 | Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients | 6.8 | 32 | Citations (PDF) |
| 81 | Romiplostim overcomes refractory secondary immune thrombocytopenia in a patient affected by serous ovarian carcinoma | 0.6 | 0 | Citations (PDF) |
| 82 | Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after Autograft: A Multicenter Retrospective Study Based on Donor Availability | 1.6 | 82 | Citations (PDF) |
| 83 | Hypermethylation of Wnt antagonist gene promoters and activation of Wnt pathway in myelodysplastic marrow cells | 0.7 | 15 | Citations (PDF) |
| 84 | Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin’s lymphoma patients | 1.5 | 38 | Citations (PDF) |
| 85 | Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience | 3.9 | 129 | Citations (PDF) |
| 86 | Hydroxyurea‐related toxicity in 3,411 patients with Ph'‐negative MPN | 6.5 | 122 | Citations (PDF) |
| 87 | Cytarabine and clofarabine after high‐dose cytarabine in relapsed or refractory AML patients | 6.5 | 27 | Citations (PDF) |
| 88 | Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: A GITMO study | 1.5 | 77 | Citations (PDF) |
| 89 | Best practice for peripheral blood progenitor cell mobilization and collection in adults and children: results of a Società Italiana Di Emaferesi e Manipolazione Cellulare (SIDEM) and Gruppo Italiano Trapianto Midollo Osseo (GITMO) consensus process | 0.8 | 55 | Citations (PDF) |
| 90 | Single dose palonosetron and dexamethasone in preventing nausea and vomiting induced by high emetogenic ABVD regimen in Hodgkin Lymphoma patients | 0.7 | 11 | Citations (PDF) |
| 91 | Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine | 0.7 | 23 | Citations (PDF) |
| 92 | Familial Hemophagocytic Lymphohistiocytosis May Present during Adulthood: Clinical and Genetic Features of a Small Series | 2.3 | 84 | Citations (PDF) |
| 93 | Human mesenchymal stromal cells preserve their stem features better when cultured in the Dulbecco's modified Eagle medium | 2.3 | 15 | Citations (PDF) |
| 94 | The impact of histopathologic examination of graft-versus-host disease in the era of reduced-intensity conditioning regimen: a study from the Gruppo Italiano Trapianto di Midollo Osseo | 2.3 | 17 | Citations (PDF) |
| 95 | Hepcidin Levels and Their Determinants in Different Types of Myelodysplastic Syndromes | 2.3 | 108 | Citations (PDF) |
| 96 | Dendritic cells with lymphocyte-stimulating activity differentiate from human CD133 positive precursorsBlood, 2011, 117, 3983-3995 | 4.8 | 11 | Citations (PDF) |
| 97 | Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosisBlood, 2011, 118, 2069-2076 | 4.8 | 149 | Citations (PDF) |
| 98 | EZH2 mutational status predicts poor survival in myelofibrosisBlood, 2011, 118, 5227-5234 | 4.8 | 250 | Citations (PDF) |
| 99 | Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid | 0.7 | 13 | Citations (PDF) |
| 100 | Impact of Dose-Dense Immunochemotherapy on Prognosis of Germinal Center and Non Germinal Center Origin of Diffuse Large B Cell Lymphoma | 1.5 | 1 | Citations (PDF) |
| 101 | Proposed definition of ‘poor mobilizer’ in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo | 2.3 | 178 | Citations (PDF) |
| 102 | Acquired severe aplastic anemia after H1N1 influenza virus vaccination successfully treated with allogeneic bone marrow transplantation | 1.5 | 17 | Citations (PDF) |
| 103 | Molecular analysis of population structure and antibiotic resistance of Klebsiella isolates from a three-year surveillance program in Florence hospitals, Italy | 2.6 | 12 | Citations (PDF) |
| 104 | High-Dose Rituximab in the Conditioning Regimen Before Allogeneic Stem Cell Transplantation Reduces the Incidence of Acute Gvhd in B-Cell LymphomasBlood, 2011, 118, 4546-4546 | 4.8 | 0 | Citations (PDF) |
| 105 | Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA GroupBlood, 2010, 116, 3171-3179 | 4.8 | 313 | Citations (PDF) |
| 106 | Oxaliplatin‐based chemotherapy (dexamethasone, high‐dose cytarabine, and oxaliplatin) ± rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma | 4.0 | 28 | Citations (PDF) |
| 107 | Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis | 7.7 | 26 | Citations (PDF) |
| 108 | Molecular Characterization of
Acinetobacter
Isolates Collected in Intensive Care Units of Six Hospitals in Florence, Italy, during a 3-Year Surveillance Program: a Population Structure Analysis | 4.0 | 17 | Citations (PDF) |
| 109 | Safety and efficacy of rituximab in patients with hepatitis C virus–related mixed cryoglobulinemia and severe liver diseaseBlood, 2010, 116, 335-342 | 4.8 | 119 | Citations (PDF) |
| 110 | High recovery of mesenchymal progenitor cells with non-density gradient separation of human bone marrow | 2.3 | 17 | Citations (PDF) |
| 111 | Safety of Bone Marrow Stem Cell Donation: A Review | 0.7 | 49 | Citations (PDF) |
| 112 | Autologous Mesenchymal Stem Cells Foster Revascularization of Ischemic Limbs in Systemic Sclerosis | 9.6 | 106 | Citations (PDF) |
| 113 | The conundrum of HLA-DRB1*14:01/*14:54 and HLA-DRB3*02:01/*02:02 mismatches in unrelated hematopoietic SCT | 2.3 | 28 | Citations (PDF) |
| 114 | IHP Interpretation Criteria of Interim-PET Scan Confirms Prognostic Impact In Early Stage Hodgkin Lymphoma Patients without Bulky DiseaseBlood, 2010, 116, 3890-3890 | 4.8 | 4 | Citations (PDF) |
| 115 | Efficacy of Low Dose Clofarabine Plus Intermediate Dose Cytarabine In An Unselected AML Refractory/Relapsed Adult PopulationBlood, 2010, 116, 4349-4349 | 4.8 | 5 | Citations (PDF) |
| 116 | Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosome–Negative Myeloproliferative Neoplasms | 1.1 | 106 | Citations (PDF) |
| 117 | Molecular Surveillance and Population Structure Analysis of Methicillin-Susceptible and Methicillin-Resistant
Staphylococcus aureus
in High-Risk Wards | 4.0 | 3 | Citations (PDF) |
| 118 | Autologous stem cell transplantation improves microcirculation in systemic sclerosis | 6.9 | 97 | Citations (PDF) |
| 119 | Prophylaxis and Treatment of Invasive Fungal Diseases in Allogeneic Stem Cell Transplantation: Results of a Consensus Process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO) | 5.2 | 52 | Citations (PDF) |
| 120 | Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: The crucial role of PTEN | 0.4 | 17 | Citations (PDF) |
| 121 | C003 Proliferative and apoptotic signalling in bone marrow cell subpopulations of myelodysplastic syndromes patients using flow-cytometry technique | 0.7 | 0 | Citations (PDF) |
| 122 | P117 Monocentric evaluation of response and tolerability of subcutaneous azacitidine in elderly MDS patients with comorbidities | 0.7 | 0 | Citations (PDF) |
| 123 | HLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: a study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry | 2.3 | 50 | Citations (PDF) |
| 124 | Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)Blood, 2009, 113, 4153-4162 | 4.8 | 415 | Citations (PDF) |
| 125 | Increase in FOXP3+ Regulatory T Cells in GVHD Skin Biopsies Is Associated with Lower Disease Severity and Treatment Response | 1.6 | 45 | Citations (PDF) |
| 126 | JAK2V617F mutation screening in patients with retinal vein thrombosis or recurrent fetal loss | 2.3 | 1 | Citations (PDF) |
| 127 | Atypical Acute Leukemia Early After Liver Transplantation | 0.7 | 3 | Citations (PDF) |
| 128 | Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated alleleBlood, 2009, 114, 1477-1483 | 4.8 | 208 | Citations (PDF) |
| 129 | Treatment options for essential thrombocythemia and polycythemia vera | 2.0 | 7 | Citations (PDF) |
| 130 | Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantationBlood, 2009, 114, 1437-1444 | 4.8 | 140 | Citations (PDF) |
| 131 | Imatinib and cardiac failure in idiopathic hypereosinophilic syndrome | 1.5 | 1 | Citations (PDF) |
| 132 | BU/melphalan and auto-SCT in AML patients in first CR: a ‘Gruppo Italiano Trapianto di Midollo Osseo (GITMO)’ retrospective study | 2.3 | 17 | Citations (PDF) |
| 133 | Imatinib as Salvage Therapy for Patients with Refractory cGVHD: the Interim Analysis of the Prospective GITMO* Multicenter Study*Gruppo Italiano Trapianto Di Midollo Osseo.Blood, 2009, 114, 3558-3558 | 4.8 | 1 | Citations (PDF) |
| 134 | Response Assessment After Induction Therapy in Diffuse Large B Cell Lymphoma (DLBCL): Role of Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) in Comparison with Computed Tomography (CT).Blood, 2009, 114, 4995-4995 | 4.8 | 1 | Citations (PDF) |
| 135 | The Association of a Salvage Treatment Containing Novel Agents Followed by Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning Regimen Improves Overall Survival and Time-to-Progression in Multiple Myeloma Patiens Relapsing After Autologous Stem Cell Transplantation: A Multicentric Retrospective Study Based On Donor Availability.Blood, 2009, 114, 4320-4320 | 4.8 | 1 | Citations (PDF) |
| 136 | Treatment of Experimental Injury of Anal Sphincters with Primary Surgical Repair and Injection of Bone Marrow-Derived Mesenchymal Stem Cells | 1.7 | 89 | Citations (PDF) |
| 137 | Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model | 1.6 | 93 | Citations (PDF) |
| 138 | Hypermethylation ofCXCR4Promoter in CD34+ Cells from Patients with Primary Myelofibrosis | 3.2 | 97 | Citations (PDF) |
| 139 | Immunohistochemical and FISH analyses identify synovitis associated with chronic GVHD after allogeneic hematopoietic SCT | 2.3 | 3 | Citations (PDF) |
| 140 | Human herpesvirus 6-associated limbic encephalitis in adult recipients of unrelated umbilical cord blood transplantation | 2.3 | 13 | Citations (PDF) |
| 141 | Stem cell transplantation for primary immunodeficiencies | 2.3 | 11 | Citations (PDF) |
| 142 | Pulmonary mucormycosis with cervical lymph node involvement in a patient with acute myeloid leukaemia: a case report | 3.2 | 4 | Citations (PDF) |
| 143 | Cord blood banking | 1.1 | 38 | Citations (PDF) |
| 144 | The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma | 2.7 | 40 | Citations (PDF) |
| 145 | PET positivity with bone marrow biopsy revealing sarcoidosis in a patient in whom bone marrow metastases had been suspected | 2.7 | 14 | Citations (PDF) |
| 146 | A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial | 2.9 | 54 | Citations (PDF) |
| 147 | Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: Implication for assessment of disease activity and treatment | 2.3 | 72 | Citations (PDF) |
| 148 | Development of human striatal anlagen after transplantation in a patient with Huntington's disease | 4.0 | 40 | Citations (PDF) |
| 149 | A Sensitive Detection Method for MPLW515L or MPLW515K Mutation in Chronic Myeloproliferative Disorders with Locked Nucleic Acid-Modified Probes and Real-Time Polymerase Chain Reaction | 2.5 | 48 | Citations (PDF) |
| 150 | Treatment Options in Myelodysplastic Syndromes: A New Frontier | 1.5 | 3 | Citations (PDF) |
| 151 | A Prospective, Open-Label Noncomparative Study with Piperacillin-Tazobactam Monotherapy as Management of Fever in Patients with Acute Leukemia | 1.5 | 2 | Citations (PDF) |
| 152 | WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)Blood, 2008, 112, 895-902 | 4.8 | 202 | Citations (PDF) |
| 153 | Haematopoietic stem cell transplantation for autoimmune disorders | 2.8 | 17 | Citations (PDF) |
| 154 | Molecular epidemiological investigation of an outbreak of Pseudomonas aeruginosa infection in an SCT unit | 2.3 | 29 | Citations (PDF) |
| 155 | Safety and Efficacy of Bendamustine with or without Rituximab in the Treatment of Heavily Pretreated Patients with Haematological Malignancies: A Multicenter Retrospective StudyBlood, 2008, 112, 4945-4945 | 4.8 | 1 | Citations (PDF) |
| 156 | Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemiaBlood, 2007, 110, 840-846 | 4.8 | 437 | Citations (PDF) |
| 157 | Insights into JAK2-V617F mutation in CML | 27.4 | 52 | Citations (PDF) |
| 158 | ATP Modulates Cell Proliferation and Elicits Two Different Electrophysiological Responses in Human Mesenchymal Stem Cells | 3.2 | 85 | Citations (PDF) |
| 159 | Liposome‐encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre‐treated with anthracyclines | 2.1 | 61 | Citations (PDF) |
| 160 | Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group | 2.3 | 55 | Citations (PDF) |
| 161 | Treatment of refractory chronic GVHD with rituximab: a GITMO study | 2.3 | 158 | Citations (PDF) |
| 162 | Event-free survival and cost-effectiveness in adult acute lymphoblastic leukaemia in first remission treated with allogeneic transplantation | 2.3 | 22 | Citations (PDF) |
| 163 | Significance of CTLA-4 and CD14 genetic polymorphisms in clinical outcome after allogeneic stem cell transplantation | 2.3 | 23 | Citations (PDF) |
| 164 | Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden | 7.7 | 363 | Citations (PDF) |
| 165 | Anaemia characterises patients with myelofibrosis harbouring MplW515L/Kmutation | 2.7 | 158 | Citations (PDF) |
| 166 | Molecular cytogenetic findings in a four-way t(1;12;5;12)(p36;p13;q33;q24) underlying the ETV6-PDGFRB fusion gene in chronic myelomonocytic leukemia | 1.2 | 14 | Citations (PDF) |
| 167 | MicroRNA expression profile in granulocytes from primary myelofibrosis patients | 0.4 | 72 | Citations (PDF) |
| 168 | Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma | 1.8 | 25 | Citations (PDF) |
| 169 | Molecular Profiling of CD34+Cells in Idiopathic Myelofibrosis Identifies a Set of Disease-Associated Genes and Reveals the Clinical Significance of Wilms' Tumor Gene 1 (WT1) | 3.2 | 117 | Citations (PDF) |
| 170 | Rituximab and chlorambucil as first-line treatment for low-grade ocular adnexal lymphomas | 1.5 | 48 | Citations (PDF) |
| 171 | Positron emission tomography in the staging of patients with Hodgkin’s lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi | 1.5 | 102 | Citations (PDF) |
| 172 | No role for CXCL12–G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia | 7.7 | 7 | Citations (PDF) |
| 173 | Use of CFDA-SE for evaluating the in vitro proliferation pattern of human mesenchymal stem cells | 2.3 | 48 | Citations (PDF) |
| 174 | Thymoglobulin Prevents Chronic Graft-versus-Host Disease, Chronic Lung Dysfunction, and Late Transplant-Related Mortality: Long-Term Follow-Up of a Randomized Trial in Patients Undergoing Unrelated Donor Transplantation | 1.6 | 346 | Citations (PDF) |
| 175 | Fatal Acute Hepatitis C Virus Infection in Patients with Hematological Malignancies | 1.5 | 2 | Citations (PDF) |
| 176 | Inconsistencies in the association between the JAK2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases | 2.7 | 11 | Citations (PDF) |
| 177 | Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study | 2.7 | 50 | Citations (PDF) |
| 178 | The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients | 7.7 | 52 | Citations (PDF) |
| 179 | Percutaneous vertebroplasty and kyphoplasty in patients with multiple myeloma | 1.8 | 32 | Citations (PDF) |
| 180 | Epstein–Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation | 1.4 | 34 | Citations (PDF) |
| 181 | Low dose velcade, thalidomide and dexamethasone (LD-VTD): An effective regimen for relapsed and refractory multiple myeloma patients | 1.4 | 39 | Citations (PDF) |
| 182 | Influence of the Jak2V617F Mutational Load at Diagnosis on Major Clinical Aspects in Patients with Polycythemia Vera. | 4.8 | 15 | Citations (PDF) |
| 183 | Chronic Relapsing Thrombotic Thrombocytopenic Purpura Successfully Treated with Rituximab: Case Report | 1.5 | 3 | Citations (PDF) |
| 184 | Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of lifeBlood, 2005, 105, 2601-2607 | 4.8 | 156 | Citations (PDF) |
| 185 | Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma | 2.7 | 89 | Citations (PDF) |
| 186 | Role of extracorporeal photochemotherapy in patients with refractory chronic graft-versus-host disease | 2.7 | 65 | Citations (PDF) |
| 187 | Candida krusei fungemia in an unrelated allogeneic hematopoietic stem cell transplant patient successfully treated with Caspofungin | 2.3 | 4 | Citations (PDF) |
| 188 | Clinical implications of the JAK2 V617F mutation in essential thrombocythemia | 7.7 | 240 | Citations (PDF) |
| 189 | Nephrotic Syndrome and Renal Failure After Allogeneic Stem Cell Transplantation: Novel Molecular Diagnostic Tools for a Challenging Differential Diagnosis | 1.4 | 36 | Citations (PDF) |
| 190 | Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma | 4.0 | 8 | Citations (PDF) |
| 191 | Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials | 9.9 | 24 | Citations (PDF) |
| 192 | Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma | 9.9 | 22 | Citations (PDF) |
| 193 | Abnormalities of GATA-1 in Megakaryocytes from Patients with Idiopathic Myelofibrosis | 3.4 | 69 | Citations (PDF) |
| 194 | Allogeneic Stem Cell Transplantation | 0.7 | 25 | Citations (PDF) |
| 195 | Internal Tandem Duplications ofFlt3Gene (Flt3/ITD) Predicts a Poor Post-Remission Outcome in Adult Patients with Acute Non-Promyelocytic Leukemia | 1.4 | 20 | Citations (PDF) |
| 196 | Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia | 34.5 | 1,078 | Citations (PDF) |
| 197 | Incidence and Management of Proven and Probable Fungal Infections in Patients with Acute Leukemia: A Single Center Experience | 1.5 | 2 | Citations (PDF) |
| 198 | PRV-1
, erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia | 2.7 | 21 | Citations (PDF) |
| 199 | Treatment of large cell lymphoma in elderly patients with a mitoxantrone, cyclophosphamide, etoposide, and prednisone regimen | 4.0 | 12 | Citations (PDF) |
| 200 | Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation | 2.3 | 259 | Citations (PDF) |
| 201 | High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors | 2.3 | 15 | Citations (PDF) |
| 202 | Impact of marrow unrelated donor search duration on outcome of children with acute lymphoblastic leukemia in second remission | 2.3 | 26 | Citations (PDF) |
| 203 | PET Scan Evaluation of Thymic Mass After Autologous Peripheral Blood Stem-cell Transplantation in an Adult with Non-Hodgkin's Lymphoma | 1.4 | 13 | Citations (PDF) |
| 204 | Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT) | 2.7 | 102 | Citations (PDF) |
| 205 | Second Allogeneic Bone Marrow Transplantation in Acute Leukemia: Results of a Survey by the European Cooperative Group for Blood and Marrow Transplantation | 16.9 | 180 | Citations (PDF) |
| 206 | Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO)Blood, 2001, 98, 2942-2947 | 4.8 | 521 | Citations (PDF) |
| 207 | Selective ex vivo
expansion of cytomegalovirus-specific CD4+
and CD8+
T lymphocytes using dendritic cells pulsed with a human leucocyte antigen A*0201-restricted peptide | 2.7 | 21 | Citations (PDF) |
| 208 | No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission | 2.7 | 67 | Citations (PDF) |
| 209 | An Open Evaluation of Triple Antibiotic Therapy Including Vancomycin for Febrile Bone Marrow Transplant Recipients with Severe Neutropenia | 1.5 | 2 | Citations (PDF) |
| 210 | Retrospective survival analysis and cost-effectiveness evaluation of second allogeneic bone marrow transplantation in patients with acute leukemia | 2.3 | 22 | Citations (PDF) |
| 211 | Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation | 2.3 | 84 | Citations (PDF) |
| 212 | Detection of contaminating tumor cells by RT-PCR in breast cancer patients | 2.3 | 1 | Citations (PDF) |
| 213 | Human polyomavirus BK (BKV) load and haemorrhagic cystitis in bone marrow transplantation patients | 3.0 | 136 | Citations (PDF) |
| 214 | A Reappraisal of the Histopathologic Criteria for the Diagnosis of Cutaneous Allogeneic Acute Graft-vs-Host Disease | 0.7 | 34 | Citations (PDF) |
| 215 | Fatal herpesvirus 6 encephalitis after unrelated bone marrow transplant | 2.3 | 67 | Citations (PDF) |
| 216 | Evaluation of breast tumour cell contamination in the bone marrow and leukapheresis collections by RT‐PCR for cytokeratin‐19 mRNA | 2.7 | 55 | Citations (PDF) |
| 217 | Randomized Trial Comparing Netilmicin plus Imipenem-Cilastatin versus Netilmicin plus Ceftazidime as Empiric Therapy for Febrile Neutropenic Bone Marrow Transplant Recipients | 1.5 | 7 | Citations (PDF) |
| 218 | Second allogeneic bone marrow transplantation in acute leukemia: a multicenter study from the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO) | 7.7 | 56 | Citations (PDF) |
| 219 | Treatment of aplastic anaemia (AA) with antilymphocyte globulin (ALG) and methylprednisolone (MPred) with or without androgens: a randomized trial from the EBMT SAA working party | 2.7 | 111 | Citations (PDF) |
| 220 | Chemoprophylaxis of Bacterial Infections in Granulocytopenic Patients with Ciprofloxacin vs Ciprofloxacin plus Amoxicillin | 1.5 | 14 | Citations (PDF) |
| 221 | The Use of Erythropoietin in the Treatment of Post-bone Marrow Transplatation Anemia | 1.2 | 3 | Citations (PDF) |
| 222 | Antiemetic Prophylaxis in Patients Undergoing Bone Marrow Transplantation: The Role of Ondansetron | 1.4 | 0 | Citations (PDF) |
| 223 | Recombinant Human Erythropoietin: Clinical Experience in Bone Marrow Transplantation | 1.4 | 1 | Citations (PDF) |
| 224 | Aztreonam versus Colistin-Neomycin for Selective Decontamination of the Digestive Tract in Patients Undergoing Bone Marrow Transplantation: a Randomized Study | 1.5 | 2 | Citations (PDF) |
| 225 | PKRD: a pharmacokinetic program for least-squares and bayesian analysis of repeated-dose pharmacokinetic curves | 4.6 | 6 | Citations (PDF) |
| 226 | Impaired erythropoietin production in mice treated with cyclosporin ABlood, 1991, 78, 1615-1618 | 4.8 | 23 | Citations (PDF) |
| 227 | In situ immunologic characterization of cutaneous involvement in Hodgkin's disease | 4.0 | 13 | Citations (PDF) |
| 228 | Primary cutaneous follicular centre-cell lymphoma-a lymphoproliferative disease with favourable prognosis | 1.1 | 92 | Citations (PDF) |
| 229 | Combined surgery and chemotherapy for the treatment of primary gastrointestinal intermediate- or high-grade non-Hodgkin's lymphomas | 5.5 | 51 | Citations (PDF) |
| 230 | The Influence of Ofloxacin versus Trimethoprim-Sulfamethoxazole on the Aerobic Flora in Granulocytopenic Subjects | 1.5 | 7 | Citations (PDF) |
| 231 | Neutral maltase of human granulocytes: Localization on the extracytoplasmic side of the plasma membrane and some properties | 0.9 | 1 | Citations (PDF) |
| 232 | Treatment-related leukemia in Hodgkin's disease: A multi-institution study on 75 cases | 2.1 | 26 | Citations (PDF) |
| 233 | Phenotypic and Ultrastructural Profile of M5 Leukemia Cells in Peripheral Blood and Skin Infiltrate | 1.4 | 2 | Citations (PDF) |
| 234 | Acute leukaemia in patients treated for Hodgkin's disease | 2.7 | 55 | Citations (PDF) |
| 235 | Displacement of T Lymphocytes with the ‘Helper/Inducer’ Phenotype from Peripheral Blood to Lymphoid Organs in Untreated Patients with Hodgkin's Disease | 0.0 | 41 | Citations (PDF) |
| 236 | Second malignancy in patients treated for Hodgkin's disease | 4.0 | 133 | Citations (PDF) |
| 237 | Title is missing! 0 | | 1 | Citations (PDF) |
